Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing...( WALTHAM Mass. Jan. 27 /-Interleukin G...),Health
Navigation Links
Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards
Date:1/27/2009
WALTHAM, Mass., Jan. 27 /PRNewswire-FirstCall/ --Interleukin Genetics, Inc. (NYSE Alternext US: ILI) today announced that the Company has submitted a plan to the NYSE Alternext US LLC (the "Exchange") that outlines the Company's strategy to regain compliance with the Exchange's continued listing requirements. The Company expects the Exchange to formally respond to the submitted plan within 45 days.
If the plan is accepted, the Company may be able to continue its listing up to June 23, 2010 during which time it will be subject to periodic review to ensure the Company is making progress consistent with the plan. Should the plan not be accepted by the Exchange, the Company will have the opportunity to appeal that ruling.
About Interleukin Genetics
Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit
| SOURCE Interleukin Genetics, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Genetics Hold Promise, Challenges for Cancer Care
Post Your Comments:
(Date:12/4/2009)...ire/ -- Pamela Bowen, Chief Information Officer at...or the "Chief Innovation Officer" Appy Award for t...cloud computing. Appy Award recipients are nominat...RM or the Force.com platform in bringing new level...artner, service, support or IT organizations. ,...
(Date:12/4/2009)... cancers, particularly Ewing sarcomas and tumors o...tudy published online December 4 in the Journal o...as undertaken because there is limited research on...) for pediatric cancer patients. , Karen Wasilew...lood Disorders Service, Children,s Healthcare of A...
(Date:12/4/2009)... from the School of Medicine,s Department of Nutri...ch products of lipid peroxidation and some drugs o... The pathways were identified by a combination of ...dings shed new light on the mechanism of action of...wn as "the date rape drug." The manuscript publish...
(Date:12/4/2009)...phenomenon that was started by people that were lo...al work in the US, Canada, and other countries. In... have found that Mexican Dental Vacation is a grea... (PRWEB) December 4, 2009 -- Aft...n Dental Vacation is seeing their best year ever, ...
(Date:12/4/2009)...ators to crack down on abuse of opioid medications...The makers of 24 different prescription painkiller...s to curb the abuse of these opioid drugs. , T...re from U.S. Food and Drug Administration official...doses that occur with these medications each year,...
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2[0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist[0] News brief -- childhood cancer survivor study report: Late recurrence is a risk for some cancers[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor [0] Makers of Powerful Painkillers Present Safety Plans
..., yet 2 million people die of cardiovascular disea...e is now affecting younger generations due to unhe...ture deaths. Recent studies have highlighted the ... to develop national strategies to combat heart di...
...M) has,focused its culinary expertise this time to...u salivating for more. Italians have known for cen...age as natural as spaghetti and,meatballs. Now Twi...ew., (Photo: http://www.newscom.com/cgi-bin/prnh...
...lutions, Inc.,(Accuro) (http://www.accurohealth.c...cle management market with the acquisition of TPMS...rovides contract management services to a,strong c...MS,personnel to continue to provide the excellent ...
... Hyperion,Therapeutics, Inc., a privately held bio...S. Zoth has been elected to the company,s Board of...e President and Chief,Financial Officer of MedImmu...n discussing her appointment, Ms. Zoth commented, ...
...ncrease the bronchoscopy market, to approximately...earch Group, WALT...,Research Group,s US Markets for ENT & Bronchoscop... to $180 million by 2012., To date, the majority ...
...ific Corporation (NYSE: BSX ) today announced the...ounsel. Pratt is a nationally known,attorney speci...ation. He,will hold the title of "Executive Vice P...cer Jim Tobin. He plans to join,the Company May 1s...
Other Medicine News:Health News:Joining efforts to tackle heart disease 2Health News:Joining efforts to tackle heart disease 3Health News:New Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free Connoisseurs 2Health News:Hyperion Therapeutics Elects Lota Zoth to Board of Directors 2Health News:Interventional Pulmonology Creeping into Bronchoscopy Market 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 3Joining efforts to tackle heart diseaseNew Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free ConnoisseursAccuro Healthcare Solutions Acquires TPMSHyperion Therapeutics Elects Lota Zoth to Board of DirectorsInterventional Pulmonology Creeping into Bronchoscopy MarketBoston Scientific Announces Appointment of Timothy Pratt as General Counsel
(Date:12/4/2009)..., , BILLERICA, Mass., Dec. 4 /PRNewswi...y-owned subsidiary of Volcano Corporation (Nasdaq:...and successful testing of a novel integrated light...ves this proprietary optical engine design raises ... limitations of laser-based designs for swept sour...
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 /PRNewswire-First...r the "Company") (OTC Bulletin Board: NWBO) announ...has allowed its patent application on a system for...re of the Company,s DCVax® therapeutic cancer... key to the very high concentration of dendritic c...
(Date:12/3/2009)..., , ALISO VIEJO, Calif. and STATE COLLEG...SoftGenetics today announced the signing of an agr... services using SoftGenetics, NextGENe software fo... Ambry. ,, (Logo: http://www.newscom.com/cg...sheidt PhD, Ambry,s CSO said, "Our team at Ambry h...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 1Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 2Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 4Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 1Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 3Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 1Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 2Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 3[0] Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging[0] Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing[0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
...s of Disease Activity as Measured,by MRI and Relap...ech, Inc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasda... II clinical study of Rituxan®,(rituximab) in ...is,(RRMS) were presented today at the American Aca...ituxan is a therapeutic antibody,that targets and ...
... reduced by 40 percent compared,to delayed treatme...lthCare,Pharmaceuticals announced today new data, ...on(R) (interferon beta-1b) treatment in,patients w... (MS),can significantly reduce the risk of permane...nded Disability Status Scale,(EDSS) by 40 percent(...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |